Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Abraxis BioScience, Inc.
Abraxis BioScience Announces Approval to Market ABRAXANE for Metastatic Breast Cancer in China
August 1st, 2008
Abraxis BioScience, Inc. (NASDAQ:ABII), a fully integrated biotechnology company, announced it has received approval from the China State Food and Drug Administration to market ABRAXANE(R) Paclitaxel for Injection (Albumin Bound) for the treatment of breast cancer after failure of standard chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. The Phase III clinical trials in the U.S. and China on which this approval was based demonstrated that ABRAXANE doubled the response rate, significantly prolonged time to tumor progression, and in the U.S. trial, significantly improved overall survival versus Taxol(R) in the approved indication. ...
Source: Health Business Week (2008-08-01)
|
